Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment.

Comen EA, Bowman RL, Kleppe M.

Front Cell Dev Biol. 2018 Jun 12;6:56. doi: 10.3389/fcell.2018.00056. eCollection 2018. Review.

2.

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL.

Cancer Cell. 2018 Apr 9;33(4):785-787. doi: 10.1016/j.ccell.2018.03.024. No abstract available.

3.

Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis.

Kleppe M, Spitzer MH, Li S, Hill CE, Dong L, Papalexi E, De Groote S, Bowman RL, Keller M, Koppikar P, Rapaport FT, Teruya-Feldstein J, Gandara J, Mason CE, Nolan GP, Levine RL.

Cell Stem Cell. 2018 Feb 1;22(2):277. doi: 10.1016/j.stem.2017.12.018. No abstract available.

PMID:
29395057
4.

TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis.

Fang J, Muto T, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, Sampson L, Wellendorf AM, Chetal K, Choi K, Salomonis N, Choi Y, Zheng Y, Cancelas JA, Levine RL, Starczynowski DT.

Cell Rep. 2018 Jan 30;22(5):1250-1262. doi: 10.1016/j.celrep.2018.01.013.

5.

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL.

Cancer Cell. 2018 Jan 8;33(1):29-43.e7. doi: 10.1016/j.ccell.2017.11.009. Epub 2017 Dec 14. Erratum in: Cancer Cell. 2018 Apr 9;33(4):785-787.

PMID:
29249691
6.

Biorelevant Media Slows the Solution-Mediated Phase Transformation of Amorphous Spironolactone.

Kleppe MS, Haskell RJ, Bogner RH.

J Pharm Sci. 2018 Jan;107(1):426-435. doi: 10.1016/j.xphs.2017.10.041. Epub 2017 Nov 6.

PMID:
29122582
7.

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms.

Hobbs GS, Hanasoge Somasundara AV, Kleppe M, Litvin R, Arcila M, Ahn J, McKenney AS, Knapp K, Ptashkin R, Weinstein H, Heinemann MH, Francis J, Chanel S, Berman E, Mauro M, Tallman MS, Heaney ML, Levine RL, Rampal RK.

Haematologica. 2018 Jan;103(1):e5-e9. doi: 10.3324/haematol.2017.177600. Epub 2017 Oct 19. No abstract available.

8.

Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis.

Kleppe M, Spitzer MH, Li S, Hill CE, Dong L, Papalexi E, De Groote S, Bowman RL, Keller M, Koppikar P, Rapaport FT, Teruya-Feldstein J, Gandara J, Mason CE, Nolan GP, Levine RL.

Cell Stem Cell. 2017 Oct 5;21(4):489-501.e7. doi: 10.1016/j.stem.2017.08.011. Epub 2017 Sep 28. Erratum in: Cell Stem Cell. 2018 Feb 1;22(2):277.

9.

A dual-process view on medication adherence: The role of affect.

Kleppe M, Lacroix J, Ham J, Midden C.

J Health Psychol. 2017 Feb 1:1359105317690599. doi: 10.1177/1359105317690599. [Epub ahead of print]

PMID:
28810401
10.

'A necessary evil': associations with taking medication and their relationship with medication adherence.

Kleppe M, Lacroix J, Ham J, Midden C.

Psychol Health Med. 2017 Dec;22(10):1217-1223. doi: 10.1080/13548506.2017.1316412. Epub 2017 Apr 9.

PMID:
28393554
11.

Endothelial-specific inhibition of NF-κB enhances functional haematopoiesis.

Poulos MG, Ramalingam P, Gutkin MC, Kleppe M, Ginsberg M, Crowley MJ, Elemento O, Levine RL, Rafii S, Kitajewski J, Greenblatt MB, Shim JH, Butler JM.

Nat Commun. 2016 Dec 21;7:13829. doi: 10.1038/ncomms13829.

12.

Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease.

De Decker K, Speth S, Ter Brugge HG, Bart J, Massuger LFAG, Kleppe M, Kooreman LFS, Kruitwagen RFPM, Kruse AJ.

Gynecol Oncol. 2017 Feb;144(2):285-289. doi: 10.1016/j.ygyno.2016.11.035. Epub 2016 Nov 23.

PMID:
27889017
13.

An Unexpected Chink in the Transcriptional Armor of Plasmacytoid Dendritic Neoplasms.

Kleppe M, Levine RL.

Cancer Cell. 2016 Nov 14;30(5):659-660. doi: 10.1016/j.ccell.2016.10.016.

14.

Comparison of Intraoperative γ-Probe Imaging and Postoperative SPECT/CT in Detection of Sentinel Nodes Related to the Ovary.

Speth SC, Kruitwagen RF, Kleppe M, Pooters IN, Van Gorp T, Slangen BF, Brans B.

J Nucl Med. 2017 Feb;58(2):243-245. doi: 10.2967/jnumed.116.183426. Epub 2016 Oct 13.

15.

The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer.

Kleppe M, van der Aa MA, Van Gorp T, Slangen BF, Kruitwagen RF.

Eur J Cancer. 2016 Oct;66:83-90. doi: 10.1016/j.ejca.2016.07.015. Epub 2016 Aug 15.

PMID:
27536891
16.

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Sanchez Martin M, Dong L, Tallman MS, Paietta E, Wang K, He J, Lipson D, Stephens P, Miller V, Rowe JM, Teruya-Feldstein J, Mullighan CG, Ferrando AA, Krivtsov A, Armstrong S, Leung L, Ochiana SO, Chiosis G, Levine RL, Kleppe M.

Blood. 2015 Nov 26;126(22):2479-83. doi: 10.1182/blood-2015-03-635821. Epub 2015 Oct 6.

17.

Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer.

Kleppe M, Kraima AC, Kruitwagen RF, Van Gorp T, Smit NN, van Munsteren JC, DeRuiter MC.

Int J Gynecol Cancer. 2015 Oct;25(8):1405-14. doi: 10.1097/IGC.0000000000000514.

18.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Dammassa E, Romanet V, Dölemeyer A, Zender M, Heinlein M, Rampal R, Weinberg RS, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL.

Cancer Cell. 2015 Jul 13;28(1):15-28. doi: 10.1016/j.ccell.2015.06.006.

19.

Somatic mutations in leukocytes infiltrating primary breast cancers.

Kleppe M, Comen E, Wen HY, Bastian L, Blum B, Rapaport FT, Keller M, Granot Z, Socci N, Viale A, You D, Benezra R, Weigelt B, Brogi E, Berger MF, Reis-Filho JS, Levine RL, Norton L.

NPJ Breast Cancer. 2015 Jun 10;1:15005. doi: 10.1038/npjbcancer.2015.5. eCollection 2015.

20.

Mathematical Models to Explore Potential Effects of Supersaturation and Precipitation on Oral Bioavailability of Poorly Soluble Drugs.

Kleppe MS, Forney-Stevens KM, Haskell RJ, Bogner RH.

AAPS J. 2015 Jul;17(4):902-17. doi: 10.1208/s12248-015-9748-2. Epub 2015 Apr 8.

21.

The development of the ProMAS: a Probabilistic Medication Adherence Scale.

Kleppe M, Lacroix J, Ham J, Midden C.

Patient Prefer Adherence. 2015 Mar 2;9:355-67. doi: 10.2147/PPA.S76749. eCollection 2015.

22.

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL.

Cancer Discov. 2015 Mar;5(3):316-31. doi: 10.1158/2159-8290.CD-14-0736. Epub 2015 Jan 8.

23.

The detection of sentinel nodes in ovarian cancer: a feasibility study.

Kleppe M, Brans B, Van Gorp T, Slangen BF, Kruse AJ, Pooters IN, Lotz MG, Van de Vijver KK, Kruitwagen RF.

J Nucl Med. 2014 Nov;55(11):1799-804. doi: 10.2967/jnumed.114.144329. Epub 2014 Oct 20.

24.

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis.

Meyer SC, Keller MD, Woods BA, LaFave LM, Bastian L, Kleppe M, Bhagwat N, Marubayashi S, Levine RL.

Blood. 2014 Oct 2;124(14):2280-4. doi: 10.1182/blood-2014-03-560441. Epub 2014 Aug 12.

25.

Tumor heterogeneity confounds and illuminates: assessing the implications.

Kleppe M, Levine RL.

Nat Med. 2014 Apr;20(4):342-4. doi: 10.1038/nm.3522.

PMID:
24710377
26.

Mucinous borderline tumours of the ovary and the appendix: a retrospective study and overview of the literature.

Kleppe M, Bruls J, Van Gorp T, Massuger L, Slangen BF, Van de Vijver KK, Kruse AJ, Kruitwagen RF.

Gynecol Oncol. 2014 May;133(2):155-8. doi: 10.1016/j.ygyno.2014.02.013. Epub 2014 Feb 16. Review.

PMID:
24552756
27.

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.

Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, Qi J, Kleppe M, Patel HJ, Shah SK, Taldone T, Bradner JE, Chiosis G, Levine RL.

Blood. 2014 Mar 27;123(13):2075-83. doi: 10.1182/blood-2014-01-547760. Epub 2014 Jan 27.

28.

Lymph-node metastasis in stage I and II sex cord stromal and malignant germ cell tumours of the ovary: a systematic review.

Kleppe M, Amkreutz LC, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF.

Gynecol Oncol. 2014 Apr;133(1):124-7. doi: 10.1016/j.ygyno.2014.01.011. Epub 2014 Jan 16. Review.

PMID:
24440833
29.

Effect of total motile sperm count in intra-uterine insemination on ongoing pregnancy rate.

Kleppe M, van Hooff MH, Rhemrev JP.

Andrologia. 2014 Dec;46(10):1183-8. doi: 10.1111/and.12212. Epub 2014 Jan 6.

PMID:
24386953
30.

Toll-like receptor alterations in myelodysplastic syndrome.

Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G.

Leukemia. 2013 Sep;27(9):1832-40. doi: 10.1038/leu.2013.180. Epub 2013 Jun 14.

31.

TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT.

Cancer Discov. 2013 May;3(5):564-77. doi: 10.1158/2159-8290.CD-12-0504. Epub 2013 Mar 7.

32.

Sentinel node in ovarian cancer: study protocol for a phase 1 study.

Kleppe M, Van Gorp T, Slangen BF, Kruse AJ, Brans B, Pooters IN, Van de Vijver KK, Kruitwagen RF.

Trials. 2013 Feb 15;14:47. doi: 10.1186/1745-6215-14-47.

33.

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG.

Cancer Cell. 2012 Aug 14;22(2):153-66. doi: 10.1016/j.ccr.2012.06.005.

34.

New pieces of a puzzle: the current biological picture of MPN.

Kleppe M, Levine RL.

Biochim Biophys Acta. 2012 Dec;1826(2):415-22. doi: 10.1016/j.bbcan.2012.07.002. Epub 2012 Jul 20. Review.

PMID:
22824378
35.

Targeting β-catenin in CML: leukemia stem cells beware!

Kleppe M, Levine RL.

Cell Stem Cell. 2012 Apr 6;10(4):351-3. doi: 10.1016/j.stem.2012.03.006.

36.

Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.

Porcu M, Kleppe M, Gianfelici V, Geerdens E, De Keersmaecker K, Tartaglia M, Foà R, Soulier J, Cauwelier B, Uyttebroeck A, Macintyre E, Vandenberghe P, Asnafi V, Cools J.

Blood. 2012 May 10;119(19):4476-9. doi: 10.1182/blood-2011-09-379958. Epub 2012 Mar 21.

37.

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG.

Nature. 2012 Jan 11;481(7380):157-63. doi: 10.1038/nature10725.

38.

Lymph node metastasis in stages I and II ovarian cancer: a review.

Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF.

Gynecol Oncol. 2011 Dec;123(3):610-4. doi: 10.1016/j.ygyno.2011.09.013. Epub 2011 Oct 6. Review.

PMID:
21982047
39.

Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma.

Kleppe M, Tousseyn T, Geissinger E, Kalender Atak Z, Aerts S, Rosenwald A, Wlodarska I, Cools J.

Haematologica. 2011 Nov;96(11):1723-7. doi: 10.3324/haematol.2011.041921. Epub 2011 Jul 26.

40.

Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.

Schmidt T, Kharabi Masouleh B, Loges S, Cauwenberghs S, Fraisl P, Maes C, Jonckx B, De Keersmaecker K, Kleppe M, Tjwa M, Schenk T, Vinckier S, Fragoso R, De Mol M, Beel K, Dias S, Verfaillie C, Clark RE, Brümmendorf TH, Vandenberghe P, Rafii S, Holyoake T, Hochhaus A, Cools J, Karin M, Carmeliet G, Dewerchin M, Carmeliet P.

Cancer Cell. 2011 Jun 14;19(6):740-53. doi: 10.1016/j.ccr.2011.05.007.

41.

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.

Kleppe M, Soulier J, Asnafi V, Mentens N, Hornakova T, Knoops L, Constantinescu S, Sigaux F, Meijerink JP, Vandenberghe P, Tartaglia M, Foa R, Macintyre E, Haferlach T, Cools J.

Blood. 2011 Jun 30;117(26):7090-8. doi: 10.1182/blood-2010-10-314286. Epub 2011 May 6.

42.

MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context.

Kleppe M, Mentens N, Tousseyn T, Wlodarska I, Cools J.

Haematologica. 2011 May;96(5):779-83. doi: 10.3324/haematol.2010.035931. Epub 2010 Dec 29.

43.

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.

Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, Graux C, Van Roosbroeck K, Ferrando AA, Langerak AW, Meijerink JP, Sigaux F, Haferlach T, Wlodarska I, Vandenberghe P, Soulier J, Cools J.

Nat Genet. 2010 Jun;42(6):530-5. doi: 10.1038/ng.587. Epub 2010 May 16.

Supplemental Content

Loading ...
Support Center